Hematologic Malignancies Program

血液系统恶性肿瘤研究项目总结 血液肿瘤项目（HMP）由51名科学家和来自7个国家的临床研究人员组成。 在罗切斯特，明尼苏达州（MCR），亚利桑那州（MCA）和佛罗里达（MCF）的马约诊所的部门。该计划是共同的- 由Ansell博士（MCR）、Bergsagel博士（MCA）和Chanan-Khan博士（MCF）领导。HMP的目的是1）调查 血液恶性肿瘤的流行病学和进展机制，2）表征分子和 细胞生物学的血液恶性肿瘤，以确定新的治疗目标，和3）开发和测试新的 治疗为了实现这些目标，HMP分为4个疾病组（DG），包括 基础和转化研究科学家、血液病理学家和临床医生。总干事每周开会， 每两周讨论一次研究结果、临床试验活动和使用生物样本库样本的请求， 确保研究能够满足我们所在地区患者的需求。年度同行评审 HMP成员的资金为460万美元，其中93%来自国家癌症研究所。包括2个孢子 （淋巴瘤和多发性骨髓瘤），15 R 01，2 R41，1 R21，1 U 54，5多发性骨髓瘤研究基金会 和2个白血病和淋巴瘤协会赠款。自2012年以来，HMP已经招募了10名新科学家， 专注于从细胞信号传导到癌症生存的关键研究领域。主要科学贡献 自2012年以来，HMP包括在批准纳武利尤单抗治疗霍奇金淋巴瘤方面发挥重要作用， 全基因组关联研究（GWAS）确定大细胞淋巴瘤的易感基因座， 确定ibrutinb在CLL中作用的试验，以及在包括硼替佐米在内的一线治疗中的试验中的领导作用， 多发性骨髓瘤HMP继续拥有一个强大的临床试验计划，招募了500多名患者 每年的临床治疗试验。自2002年以来，会员共发表了1172篇文献， 2013年，其中43%是方案内的，30%是方案间的。HMP成员拥有广泛的 与基因和病毒治疗，实验治疗和遗传学成员的合作 流行病学和风险评估方案。HMP成员广泛使用众多共享 资源，大量使用生物标本采集和处理，生物统计学和药学。 与HMP有关的研究继续得到重要的机构和慈善机构（Predolin基金会）的支持。在 在下一个资助期，我们将指导年轻的研究人员，并专注于开发整合基因组的工具。 为我们的患者提供个性化的护理计划。

HEMATOLOGIC MALIGNANCIES PROGRAM PROJECT SUMMARY The Hematologic Malignancies Program (HMP) is composed of 51 scientists, and clinical investigators from 7 departments at Mayo Clinic in Rochester, MN (MCR), Arizona (MCA), and Florida (MCF). The Program is co- led by Drs. Ansell (MCR), Bergsagel (MCA) and Chanan-Khan (MCF). The HMP aims are to 1) investigate the epidemiology of hematologic malignancies and mechanisms of progression, 2) characterize the molecular and cell biology of hematologic malignancies to identify new therapeutic targets, and 3) develop and test new therapies. To accomplish these aims, the HMP is organized into 4 disease groups (DGs) that are composed of basic and translational research scientists, hematopathologists, and clinicians. The DGs meet weekly or biweekly to discuss research results, clinical trial activities, and requests for use of biobank samples and ensure that research is meeting the needs of the patients in our catchment area. Annual peer-reviewed direct funding to HMP members is $4.6M, with 93% from the National Cancer Institute. This includes 2 SPOREs (Lymphoma and Multiple Myeloma), 15 R01s, 2 R41s, 1 R21, 1 U54, 5 Multiple Myeloma Research Foundation and 2 Leukemia and Lymphoma Society grants. Since 2012, the HMP has recruited 10 new scientists who focus on key research areas ranging from cell signaling to cancer survivorship. Major scientific contributions by the HMP since 2012 include a major role in the approval of nivolumab in Hodgkin lymphoma, leadership in genome wide association studies (GWAS) identifying susceptibility loci in large cell lymphoma, leadership in trials establishing the role of ibrutinb in CLL, and leadership in trials including bortezomib in frontline therapy for multiple myeloma. The HMP continues to have a robust clinical trials program that enrolls over 500 patients each year to therapeutic clinical trials. Members have contributed 1172 publications to the literature since 2013, 43% of which are intraprogrammatic and 30% interprogrammatic. HMP members have extensive collaborations with members in the Gene and Virus Therapy, Experimental Therapeutics, and Genetic Epidemiology and Risk Assessment Programs. HMP members make extensive use of numerous Shared Resources, with substantial use of Biospecimens Accessioning & Processing, Biostatistics, and Pharmacy. Significant institutional and philanthropic (Predolin Foundation) support continues for HMP-related research. In the next funding period, we will mentor young investigators and focus on developing tools to integrate genomic information into the individual care plans for our patients.